These 2 Companies Have No Competition
Warren Buffett has long championed the idea of investing in companies with durable competitive advantages. He believes that a business with true "moat" can more easily defend its market share from competitors and generate strong returns for shareholders
But if investing a company with a strong moat is a great idea, wouldn't it be even better to buy one that has no direct competition at all? Let's take a closer look at two companies that are void of rivals right now: Novocure (NASDAQ: NVCR), and Acadia Pharmaceuticals (NASDAQ: ACAD).
Image source: Getty Images.
Source: Fool.com
Acadia Pharmaceuticals Aktie
25,90 €
1,65 %
Die Acadia Pharmaceuticals Aktie steht ausgezeichnet da: Nur Buy-Einschätzungen und keine Sell-Einschätzungen.
Ein leichtes Potenzial nach oben für Acadia Pharmaceuticals mit einem Kursziel von 29 € gegenüber dem aktuellen Kurs von 25.9 €.
